Assistant Professor, Department of Medicine (Rheumatology)
Dr. Anna Broder's research interests include clinical and translational research in systemic lupus, antiphospholipid syndrome and other rheumatologic diseases. She is especially interested in the relationship between antiphospholipid antibodies and cardiovascular disease. She is the principal investigator for the Consortium of Rheumatology Researchers of North America, Inc. (CORRONA) registry that collects information about patients with rheumatoid and psoriatic arthritis.
Dr. Broder is a board-certified rheumatologist specializing in lupus, rheumatoid arthritis, psoriatic arthritis, spondyloarthropathy, and scleroderma. She works with patients who have rheumatologic diseases, including lupus and antiphospholipid syndrome as well as rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout and vasculitis. She offers community educational presentations for the Arthritis Foundation and was awarded the Arthritis Foundation New York Chapter Fellowship in Inflammatory Arthritis.
Dr. Broder completed her medical degree at the University of Medicine & Dentistry of New Jersey/Robert Wood Johnson Medical School, and a residency in internal medicine, a clinical research fellowship in rheumatology, and a Masters in Clinical Research (with honors) at Albert Einstein College of Medicine. She is a member of the American College of Rheumatology.
Dr. Broder is fluent in Russian and English.
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Block, Room 343
Bronx, NY 10461
Arthritis Today interviews Dr. Anna Broder regarding her research that found continued treatment may help extend the lives of lupus patients with end-stage renal disease. Dr. Broder is assistant professor of medicine.
Renal & Urology News interviews Dr. Anna Broder about her research that found the chance of survival for lupus patients with end-stage renal disease improved with frequent rheumatologist follow-up and continued immunosuppressive treatment.